This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:othertreatments:corticosteroids [11.05.2010] – paulalbert | home:othertreatments:corticosteroids [03.06.2011] – external edit 127.0.0.1 | ||
---|---|---|---|
Line 91: | Line 91: | ||
Table 3 in the paper shows how, for the majority of patients, markers of the disease process remained unchanged. | Table 3 in the paper shows how, for the majority of patients, markers of the disease process remained unchanged. | ||
- | ^ ^FVC ^FEV1 ^ CXR ^Dyspnea^^^ | + | ^FVC ^FEV1 ^ CXR ^Dyspnea^ |
|Improved | |Improved | ||
|Unchanged |57.7% (124) |56.7% (122) | |Unchanged |57.7% (124) |56.7% (122) | ||
Line 129: | Line 129: | ||
- | ^System or function ^ Side effect^^ | + | ^System or function ^ Side effect^ |
|brain | |brain | ||
- | |bone | + | |bone |
- | |endocrine |suppression of adrenal response(({{pubmed> | + | |endocrine |suppression of adrenal response(({{pubmed> |
- | |eyes |cataracts(({{pubmed> | + | |eyes |cataracts(({{pubmed> |
|gastrointestinal |gastrointestinal hemorrhage(({{pubmed> | |gastrointestinal |gastrointestinal hemorrhage(({{pubmed> | ||
- | |muscle | + | |muscle |
|psychological |dementia(({{pubmed> | |psychological |dementia(({{pubmed> | ||
|sexual, female |menstruation disturbance(({{pubmed> | |sexual, female |menstruation disturbance(({{pubmed> | ||
- | |sexual, male |decrease testosterone(({{pubmed> | + | |sexual, male |decrease testosterone(({{pubmed> |
- | |skin |skin atrophy(({{pubmed> | + | |skin |skin atrophy(({{pubmed> |